Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 28 · below the Ichimoku cloud · RSI 32 · MACD below its signal · 7% above its 52-week low
| 6.30 | 52-week high | +331.51% |
| 2.39 | Previous month high | +64.04% |
| 1.84 | Previous month low | +26.03% |
| 1.68 | R3 (classic) | +14.84% |
| 1.61 | R2 (classic) | +10.50% |
| 1.61 | Previous week high | +10.27% |
| 1.55 | Previous day high | +6.16% |
| 1.55 | R1 (classic) | +5.94% |
| 1.48 | Pivot | +1.60% |
| 1.46 | Price now | |
| 1.42 | Previous day low | −2.74% |
| 1.42 | S1 (classic) | −2.97% |
| 1.38 | Previous week low | −5.48% |
| 1.37 | 52-week low | −6.16% |
| 1.35 | S2 (classic) | −7.31% |
| 1.29 | S3 (classic) | −11.87% |
None of the 29 investors followed here reported a position in NGEN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NGEN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Bayley (Brian Eric)Director of Issuer | Exercise of options at price 1.52 per share. | 50K | $75.90K |
| Sep 3, 2026 | Punnett, Harold10% Security Holder of Issuer | Exercise of options at price 1.52 per share. | 17.2K | $26.08K |
| Aug 27, 2026 | Mckerracher (Krista L)Director of Issuer | Exercise of options at price 1.51 per share. | 17.6K | $26.63K |
| Aug 23, 2026 | Kaye (Randall E)Director of Issuer | Exercise of options at price 1.52 per share. | 9K | $13.61K |
| Jul 27, 2026 | Ruffolo (John)Director of Issuer | Acquisition in the public market at price 1.64 per share. | 200 | $328 |
| Jun 29, 2026 | Rogers (Adam)Director of Issuer | Compensation for services at price 2.56 per share. | 37.8K | $96.88K |
| Jun 29, 2026 | Rogers (Adam)Director of Issuer | Compensation for services at price 2.56 per share. | 61.7K | $158.23K |
| May 26, 2026 | Ruffolo (John)Director of Issuer | Acquisition in the public market at price 2.08 per share. | 8.8K | $18.23K |
| May 26, 2026 | Ruffolo (John)Director of Issuer | Acquisition in the public market at price 2.08 per share. | 16 | $33 |
| May 25, 2026 | Rogers (Adam)Director of Issuer | Acquisition under a prospectus at price 2.50 per share. | 800K | $2.00M |
| Apr 7, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.19 per share. | 10K | $41.91K |
| Apr 1, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.23 per share. | 5K | $21.15K |
| Mar 1, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 3.85 per share. | 10K | $38.52K |
| Feb 25, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.13 per share. | 5K | $20.64K |
| Feb 25, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.10 per share. | 5K | $20.52K |
| Feb 19, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.30 per share. | 10K | $42.91K |
| Feb 18, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.18 per share. | 10K | $41.77K |
| Feb 18, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.30 per share. | 20 | $86 |
| Feb 17, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 3.02 per share. | 10K | $30.17K |
| Feb 11, 2026 | Mckerracher (Krista L)Director of Issuer | Disposition in the public market at price 4.00 per share. | 10K | $39.96K |
TimeframesDown on the daily and weekly, mixed on the hourly and monthly.
under a flat 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -28.4 | -2.2 | -3.8 | -3.7 | -43.0 | -0.5 | -21.4 | 36.4 | -13.6 | -23.6 | −73.9% | ||
| 2025 | -10.0 | -2.4 | 4.4 | 8.7 | 74.4 | -33.6 | -1.0 | 6.9 | -11.3 | 5.1 | 72.6 | 30.8 | +156.9% |
| 2024 | 4.4 | 19.7 | -36.9 | -5.6 | -5.9 | 38.5 | 4.5 | 0.5 | -8.7 | -8.9 | 17.1 | 7.7 | +6.9% |
| 2023 | 35.7 | -14.6 | -10.7 | -5.9 | 12.1 | -4.6 | 4.0 | 17.6 | -6.9 | -5.1 | -2.2 | 55.7 | +71.4% |
| 2022 | -13.8 | -11.7 | -10.5 | 21.9 | -10.6 | -5.1 | 12.0 | -10.1 | -11.3 | -2.2 | 8.4 | -16.2 | −44.1% |
| 2021 | 12.6 | -10.7 | -20.6 | 2.4 | -23.5 | 15.5 | 12.0 | 17.0 | 13.9 | 24.2 | -1.5 | -7.4 | +22.4% |
| 2020 | 45.0 | -36.4 | -43.9 | 48.6 | 42.5 | -6.4 | -24.0 | 1.5 | -21.3 | 22.0 | 14.3 | 26.8 | +10.1% |
| 2019 | -6.2 | -4.2 | -2.7 | -3.9 | -3.4 | 15.3 | -9.0 | 51.6 | +29.1% |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Buy / hold / sell counts